Skip to main content
. 2022 Aug 18;154(9):e202213115. doi: 10.1085/jgp.202213115

Table 1.

Diagnostic cues, histological traits, and genes associated with main subtypes of E-C coupling and SOCE-related myopathies

E-C coupling–related myopathies Main clinical features Fiber phenotype Causative genes Inheritance Mechanism (RyR1 channel)
CCD ✓ Infantile nonprogressive hypotonia and motor development delay
✓ Mild proximal muscle weakness
✓ Respiratory distress
✓ High arched palate
✓ Craniofacial dysmorphism
✓ Centrally located, well-demarcated cores, spanning the whole fiber axis
✓ Predominance in type 1 fibers
✓ Increased central nuclei
RYR1 >90% AD or AR GoF, LoF
MYH7 AD Altered assembly and function of myosin dimers
MmD ✓ Axial muscle weakness, scoliosis, respiratory insufficiency, and limb joint hyperlaxity
✓ Ophthalmoplegia
✓ Arthrogryposis
✓ Hand amyotrophy
✓ Numerous cores in a limited area on longitudinal section
✓ Multiple internally located nuclei
✓ Predominance in type 1 fibers
RYR1 ∼20% (homozygosity or compound heterozygosity) AR GoF, LoF, lower protein levels
SEPN1 ∼50% AR Altered redox activity
TTN (homozygosity or compound heterozygosity) AR M-line alteration
MYH7 AD Not defined
ACTA1 AR Not defined
MEGF10 AD or AR Not defined
CACNA1S AD Lower protein levels
CNM ✓ Not progressive proximal muscle weakness
✓ Not progressive hypotonia
✓ Centralized and internalized nuclei
✓ Peripheral halos depleted of oxidative activity
✓ Cores
RYR1 ∼15% (compound heterozygosity) AR Lower protein levels
MTM1 XLR Altered vesicle trafficking
DNM2 AD Altered membrane fission
BIN1 AD Altered membrane tubulation
TTN AR M-line alterations
SPEG AR Altered interaction with MTM1 and desmin
CFTD ✓ Static or slowly progressive muscle weakness
✓ Respiratory and proximal axial weakness
✓ Ophthalmoplegia
✓ Dysphagia
✓ Facial muscle weakness
✓ Fiber size disproportion (35–40% of type 1 fibers are smaller in size than type 2 fibers)
✓ Age-related development of rods, cores, and central nuclei
RYR1 ∼20% AR Lower protein levels
ACTA1 AD Altered interaction with TPM
TPM2 AD or AR Altered interaction with actin
TPM3 AD or AR Altered interaction with actin
SEPN1 AR Altered redox activity
MYH7 AD LoF, altered interaction with myosin binding protein
LMNA AD Not defined
ZAK AR LoF
SPEG AR LoF
DuCD ✓ Ocular involvement (eyelid ptosis, ophthalmoplegia) ✓ Irregularly sized/shaped “dusty” cores (reddish-purple granular material deposition) spanning 10–50 sarcomeres
✓ Myofibrillar disorganization
RYR1 AR Lower protein levels
CRM ✓ Nonspecific clinical features, including hypotonia, muscle weakness, scoliosis, and respiratory insufficiency ✓ Nemaline bodies (rods), clustered or widely distributed along the fibers
✓ Central cores
RYR1 AD or AR GoF, LoF
CFL2 AR Protein misfolding and degradation
ACTA1 AD Altered stability or function
TPM3 AD or AR Not defined
NEB AR Not defined
MH ✓ Muscle rigidity and cardiac arrhythmia, occurring only following exposure to succinylcholine and volatile anesthetics
✓ Sustained contractures,
✓ Hyperthermia
✓ Hyperkalemia
✓ Hypermetabolism
✓ No histological features can be found in muscle fibers from MH patients RYR1 AD GoF
CACNA1S AD GoF
SOCE-related myopathies
TAM/Stormorken syndrome ✓ Muscle weakness
✓ Myalgia
✓ Cramps
✓ Increased creatine kinase levels
✓ Exercise intolerance
✓ Single- or double-walled SR tubules arranged as honeycomb-like structures in type 2 fibers
✓ Prevalence of type 1 fibers
STIM1 AD GoF
ORAI AD GoF
CASQ1 AD Altered polymerization
RYR1 AD GoF

Proteins encoded by the indicated genes and relative references are reported in the text. AD, autosomal dominant; AR, autosomal recessive; GoF, gain-of-function; LoF, loss-of-function; XLR, X-linked recessive.